PDE4D (phosphodiesterase 4D) is a cAMP-hydrolyzing enzyme that plays critical roles in cardiac, metabolic, immune, and neurological functions. As a major phosphodiesterase degrading cAMP in the heart, PDE4D regulates cardiac homeostasis through the cAMP-PKA-CREB-SIRT1 signaling pathway; PDE4D upregulation during adrenergic stress suppresses mitophagy and promotes cardiac hypertrophy and heart failure, while PDE4D inhibition ameliorates these pathologies 1. In adipose tissue, PDE4D mediates FGF1-induced inhibition of lipolysis by suppressing the cAMP-PKA axis, representing an alternate pathway to insulin-mediated metabolic control 2. PDE4D is implicated in immune regulation, where selective PDE4D inhibition promotes oligodendrocyte progenitor cell differentiation and myelin repair in multiple sclerosis models without triggering emesis-like side effects associated with pan-PDE4 inhibitors 3. Genetically, PDE4D variants associate with asthma and atopy susceptibility in pediatric populations, potentially through altered gene expression affecting immunity 4. Additionally, specific PDE4D polymorphisms (SNP45, SNP83, SNP89) increase ischemic stroke risk in Asian populations 5, and elevated intracellular cAMP from PDE4D genetic variation associates with increased schizophrenia and major depressive disorder risk 6. These findings establish PDE4D as a therapeutic target for heart failure, metabolic disorders, neuroinflammatory conditions, and psychiatric diseases.